2022
40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Koshy N, Stiff P, Abboud C, Tomlinson B, Abhyankar S, Hari P, Chen G, Al-Kadhimi Z, Sabloff M, Orozco J, Foran J, Kebriaei P, Jamieson K, Magalhaes-Silverman M, van Besien K, Schuster M, Law A, Levy M, Lazarus H, Giralt S, Berger M, Spross J, Desai A, Reddy V, Pagel J. 40 High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies. Transplantation And Cellular Therapy 2022, 28: s35-s36. DOI: 10.1016/s2666-6367(22)00201-9.Peer-Reviewed Original Research
2021
438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT)
Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT). Transplantation And Cellular Therapy 2021, 27: s362-s363. DOI: 10.1016/s2666-6367(21)00464-4.Peer-Reviewed Original Research
2019
Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations
Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2018
Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation
Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.Peer-Reviewed Original ResearchConceptsUnrelated donor allogeneic stem cell transplantationDonor allogeneic stem cell transplantationAllogeneic stem cell transplantationSingle-institution pilot studyHost disease (GVHD) prophylaxisShort-course methotrexateStem cell transplantationDisease prophylaxisCell transplantationPilot studyProphylaxisTacrolimusSirolimusTransplantationMethotrexateGraft
2017
567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT)
Mohamed S, Perreault S, Seropian S, Isufi I, Foss F, Cooper D. 567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT). Transplantation And Cellular Therapy 2017, 23: s395-s396. DOI: 10.1016/j.bbmt.2016.12.616.Peer-Reviewed Original Research
2015
Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
Cecchini M, Sznol M, Seropian S. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. Journal For ImmunoTherapy Of Cancer 2015, 3: 10. PMID: 25806109, PMCID: PMC4372324, DOI: 10.1186/s40425-015-0054-4.Peer-Reviewed Original ResearchAllogeneic stem cell transplantationStem cell transplantationMetastatic melanomaCell transplantationAllogeneic bone marrow transplantSafety of immunotherapyPost-transplant patientsBone marrow transplantHost diseaseTransplant patientsImmune therapyMarrow transplantTheoretical riskMelanomaImmunotherapyPatientsTransplantationTherapyGVHDTransplantGraftDisease
2013
Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation
Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation. Palliative & Supportive Care 2013, 12: 53-61. PMID: 24169207, DOI: 10.1017/s1478951513000552.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultAftercareAgedAnxiety DisordersCooperative BehaviorDepressive DisorderFemaleHematologic NeoplasmsHematopoietic Stem Cell TransplantationHospice and Palliative Care NursingHumansInterdisciplinary CommunicationMaleMass ScreeningMiddle AgedNurse-Patient RelationsNursing AssessmentPatient DischargePatient IsolationProblem SolvingPsychometricsReproducibility of ResultsSick RoleConceptsHematopoietic stem cell transplantationStem cell transplantationCell transplantationHigh-risk hematologic malignanciesPsychological distressNon-malignant diseasesIntense psychological distressHealth care teamOncology patientsStandard treatmentHematologic malignanciesPatient distressCare teamTransplant numbersPatientsTransplantationOverall treatmentMedical issuesDistressFamily membersTreatmentSocial strainRelapseMalignancyDisease
2010
Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis
Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nature Reviews Clinical Oncology 2010, 7: 415-420. PMID: 20404855, DOI: 10.1038/nrclinonc.2010.40.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdultAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntineoplastic AgentsCombined Modality TherapyFemaleHumansImmunosuppressive AgentsLymphohistiocytosis, HemophagocyticRemission InductionStem Cell TransplantationTransplantation, HomologousTreatment Outcome